Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)

The management of advanced lung cancer has been transformed with the identification of targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) gene rearrangements. ALK tyrosine kinase inhibitors (TKI) are established first-line treatment options in advanced ALK rearra...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Aaron C., Pavlakis, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407780/
https://www.ncbi.nlm.nih.gov/pubmed/36012123
http://dx.doi.org/10.3390/ijms23168863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407780/
https://www.ncbi.nlm.nih.gov/pubmed/36012123
http://dx.doi.org/10.3390/ijms23168863

Ejemplares similares